Navigation Links
VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
Date:11/20/2008

    International Agreement Licenses Seno's Opto-Acoustic Imaging Technology
    To VisualSonics to Enable Molecular Imaging at the Cellular Level and Aid
    in the Pursuit of Neurology, Regenerative Medicine, Inflammation, and
    Cancer Applications

TORONTO and SAN ANTONIO, TX, Nov. 20 /PRNewswire/ - VisualSonics and Seno Medical Instruments today announced the official signing of a licensing agreement providing VisualSonics exclusive rights to Seno Medical's Opto-Acoustic technology for preclinical research.

"The application of opto-acoustic technology to our Vevo(R) preclinical imaging platform is an exciting new area for VisualSonics" stated Tom Little, President and Chief Executive Officer of VisualSonics, "We will be enabling researchers to push the limits of discovery as we develop tools for intracellular and molecular imaging with VisualSonics technology and Seno Medical IP."

VisualSonics will embed Seno's opto-acoustic technology in their next generation of high-frequency ultrasound platforms and this will extend their molecular imaging capability to the sub cellular level. This combination will drive the new molecular imaging utility for the next generation of preclinical imaging with the Vevo platform.

"Seno's preclinical opto-acoustic platform technology will enable researchers to non-invasively detect and monitor biological structures, functions and processes at the cellular and molecular level as well as potentially provide the ability to monitor and quantify hypoxia (oxygenated vs. deoxygenated tissue or cells), and to reveal information on tumor development, disease progression and inflammation processes that were previously unattainable," said Janet Campbell, Chairman and CEO of Seno Medical Instruments. "For this reason, there is great interest in our opto-acoustic technology for both clinical and preclinical applications. We look forward to working with VisualSonics, a market leader, and recognize that this licensing agreement further validates the value of our platform technology."

VisualSonics, the current market leader in pre-clinical high-frequency micro-ultrasound imaging systems used for small animal research, has licensed Seno Medical Instrument's opto-acoustic imaging technology to enable researchers to non-invasively detect and monitor biological structures, functions and processes at the cellular and molecular level. Since 2003, VisualSonics has sold more than 500 of its Vevo(R) imaging systems and researchers are using them widely to generate anatomical and functional data in research areas that include angiogenesis, tumor growth, and cardiovascular disease in small animal models. The Vevo platforms current imaging capabilities assist scientists to better understand phenotypes, structure and function and to better understand how genes affect diseases and responses to treatments. Micro-ultrasound imaging provides a noninvasive tool for viewing complex biological mechanisms in real-time.

About Seno Medical Instruments, Inc.

Seno Medical Instruments, Inc. is a San Antonio based medical device developer focused on the early detection of cancer thru the use of its patented opto-acoustic technology. Opto-acoustic imaging combines light and sound to produce high-resolution, high-contrast images to indicate the presence of increased blood supply and vascular structure that surround and feed a tumor. To learn more about Seno Medical's opto-acoustic imaging technology and applications, visit www.SenoMedical.com

About VisualSonics

VisualSonics is the world's leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company's enabling technology allows researchers at the world's most prestigious pharma/biotech companies, hospitals and universities to conduct research into cardiovascular disease, cancer, and developmental biology including genetic research, phenotypic study and drug development. Only VisualSonics platforms combine high-resolution, real-time in vivo imaging with ease-of-use, portability and no negative biological effects. More information can be found at www.visualsonics.com.


'/>"/>
SOURCE VisualSonics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
5. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
6. BioMS Medical announces its intention to renew a normal course issuer bid
7. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Globus Medical Announces Record 2nd Quarter 2007 Results
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):